Session Detail


Session Title: Biomarkers 5: Breast and Gynecologic Cancers
Session Type: Poster Session
Session Start/End Time: Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Location: Hall A-E, Poster Section 1
Session Category: Clinical Research 15
Presentations:
3455: Elafin is a candidate biomarker that underlies the similarities between basal-like breast cancer and ovarian cancer
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Intidhar Labidi-Galy1, Adam Clauss2, Vivian Ng2, Sekhar Duraisamy2, Shridar Ganesan3, Ronny Drapkin2. 1Dana Farber Cancer Iinstitute, Boston, MA; 2Dana Farber Cancer Institute, Boston, MA; 3Cancer Institute of New Jersey, New Brunswick, NJ
3456: Macrophages as independent prognostic factors in small T1 breast cancers
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Roberto Carrio, Tulay Koru-Sengul, Feng Miao, Stefan Gluck, Omar Lopez, Yamil Selman, Consuelo Alvarez, Clara Milikowski, Carmen Gomez, Merce Jorda, Mehrad Nadji, Marta Torroella-Kouri. Univ. of Miami Miller School of Medicine, Miami, FL
3457: Gender-associated expression of tumor markers and a small gene set in breast carcinoma
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Sarah A. Andres, Irina A. Smolenkova, James L. Wittliff. University of Louisville, Louisville, KY
3458: An epigenomic next-generation sequencing approach to identify predictive markers for PARP inhibitor response in breast cancer cells
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Tim De Meyer1, Geert Trooskens1, Mascha K. Wibbe2, Sebastian B. Bartmann2, Manon van Engeland3, Wim Van Criekinge1, Vivianne C. Tjan-Heijnen4, Ruth Knüchel2, Jürgen Veeck2. 1Gent University, Department of Mathematical Modelling, Gent, Belgium; 2RWTH Aachen University Hospital, Institute of Pathology, Aachen, Germany; 3Maastricht University Medical Centre, Department of Pathology, Maastricht, Netherlands; 4Maastricht University Medical Centre, Division of Medical Oncology, Maastricht, Netherlands
3459: Metabolomic profiling reveals significant differences between the ductal fluid from cancerous compared to unaffected breasts
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Luisa Matos do Canto, Shawna C. Willey, Elizabeth D. Feldman, Amrita Cheema, Mohammad R. Nezami Ranjbar, Habtom W. Ressom, Bassem R. Haddad. Georgetown University, Washington, DC
3460: Tumor budding is a predictive feature for lymph node metastasis in invasive ductal breast cancer
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Mafalda Trippel1, Katrin Pfaltz1, Bodour Salhia2, André Grogg1, Inti Zlobec1, Coya F. Tapia1. 1Institute of Pathology, Bern, Switzerland; 2Translational Genomics Research Institute, Phoenix, AZ
3461: Expression levels of TOX3 and the risk allele of the associated SNP rs3803662 predict adverse outcome for breast cancer patients
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Eydis Th. Gudmundsdottir1, Rosa B. Barkardottir1, Adalgeir Arason1, Haukur Gunnarsson1, Laufey Th. Amundadottir2, Bjarni A. Agnarsson1, Oskar Th. Johannsson1, Inga Reynisdottir1. 1Landspitali-University Hospital, Reykjavik, Iceland; 2National Cancer Institute, Washington, DC
3462: High-throughput qRT-PCR expression profiling of estrogen receptor positive breast tumors
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Erica B. Schleifman, Rupal M. Desai, Jill Spoerke, Cheryl Victoria Wong, Ilma Abbas, Carol O'Brien, Garret Hampton, Timothy Wilson, Hartmut Koeppen, Rajesh Patel, Teiko Sumiyoshi, Ling Fu, Rachel Tam, Rajiv Raja, Mark Lackner. Genentech, South San Francisco, CA
3463: Nuclear localization of S6K is associated with unfavorable disease-free survival in hormone-receptor positive breast cancer cases
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Nobuko Kawaguchi-Sakita1, Rafaat Abd El-Aal Bakheet Mohamed1, Fumiaki Sato1, Takayuki Ueno1, Masahiro Kawashima1, Noriyuki Yoshida1, Wen Zhao Li1, Tomoharu Sugie1, Yoshiki Mikami1, Shigehira Saji1, Takashi Inamoto2, Masakazu Toi1. 1Kyoto University, Kyoto, Japan; 2Tenri Health Care University, Nara, Japan
3464: CEBPD (C/EBPδ) acts as a tumor suppressor in hormone receptor positive breast cancer cells and may serve as biomarker to predict the need for adjuvant therapy
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Daniel Y. Mendoza-Villanueva1, Suryun Kim1, H.Raza Ali2, Shikha Sharan1, Tapasree R. Sarkar1, Carlos Caldas2, Göran Landberg3, Esta Sterneck1. 1National Cancer Institute, Frederick, MD; 2University of Cambridge, Cambridge, United Kingdom; 3University of Manchester, Manchester, United Kingdom
3465: microRNA profiling of breast ductal lavage fluid
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Luisa Matos do Canto1, Shawna C. Willey1, Elizabeth D. Feldman1, Xin (James) Li1, Catalin Marian2, Bassem R. Haddad1. 1Georgetown University, Washington, DC; 2"Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania
3466: Reduced expression of CYLD is an independent prognostic factor in breast cancer and confers treatment resistance and migratory activity in vitro
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Mitsuhiro Hayashi1, Satoru Shinriki2, Hirofumi Jono2, Takuya Nakamura2, Jianying Guo2, Yutaka Yamamoto1, Hirotaka Iwase1, Yukio Ando2. 1Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto-City, Kumamoto, Japan; 2Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto-City, Kumamoto, Japan
3467: Identification of androgen receptor splice variants, ESR1, CYP17, and CYP19 in human breast cancer
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Gabriela Martinez, Dana Gaffney, Katherine Bell, Suso Platero, Deborah Ricci, Weimin Li, Jayaprakash D. Karkera. Janssen Pharmaceuticals, Radnor, PA
3468: NF-κB pathways are associated with increased recurrence in different subtypes of ER positive breast cancer
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Lindsay Bennett1, Clare Orange1, Elizabeth Mallon1, Julie Doughty1, Paul G. Horgan1, Andrew Paul2, Joanne Edwards1. 1University of Glasgow, Glasgow, United Kingdom; 2University of Strathclyde, Glasgow, United Kingdom
3469: The expression and prognostic significance of neutrophil gelatinase-asssociated lipocalin (NGAL) in primary breast cancer
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Lee-Su Kim1, Hae Sung Kim2. 1Hallym Univ. Sacred Heart Hospital, Hallym Univ., Anyang, Korea, Republic of; 2Chuncheon Sacred Heart Hospital, Hallym Univ., Chuncheon, Korea, Republic of
3471: Anti-NMP autoantibodies together with serum levels of death receptor 6 (DR6) detect ovarian tumors at early stage
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Animesh Barua1, Jacques S. Abramowicz1, Janice M. Bahr2, Salvatore A. Grasso1, Sameer Sharma1, Sanjib Basu1, Jacob Rotmensch1, Pincas Bitterman1. 1Rush Univ. Medical Ctr., Chicago, IL; 2Univeristy of Illinois at Urbana-Champaign, Urbana-Champaign, IL
3472: Excision repair cross complementing group 1 (ERCC1) and regulatory subunit of Ribonucleotide Reductase (RRM1) as prognostic and predictive markers for ovarian cancer
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Jun Zhou1, Quratulain Ahmed1, Wei Chen2, Xin Li2, Robert Morris2, Rouba Ali-Fehmi1, Gerold Bepler2. 1Wayne State University, Detroit, MI; 2Karmanos Cancer Institute, Detroit, MI
3473: Intra-person and inter-person biomarker variation for modeling longitudinal values of ovarian cancer early detection biomarkers
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Archana Raamanathan1, Zhen Lu1, Robert C. Bast, Jr.1, Steven J. Skates2. 1MD Anderson cancer center, Houston, TX; 2Massachusetts General Hospital and Harvard Medical School,, Boston, MA
3474: GDF15 as a serum marker of cisplatin response in ovarian cancer cells
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Daisy I. Izaguirre, Suet Yan Kwan, Zhifei Zu, Yvonne T. Tsang-Lee, Kwong-Kwok Wong. UT MD Anderson Cancer Center, Houston, TX
3475: Progranulin as a prognostic biomarker of advanced epithelial ovarian cancer
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Sharon Fitzgerald1, Minshu Yu2, John Hays2, Nicola Di Santo3, Laura Havrilesky3, Elise Kohn2. 1Walter Reed National Military Medical Center, Bethesda, MD; 2National Cancer Institute, Bethesda, MD; 3Duke University, Durham, NC
3476: Higher plasma levels of heparan sulfate are associated with improved survival of patients with advanced ovarian cancer
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Matthew S. Block, Matthew J. Maurer, Krista M. Goergen, Courtney L. Erskine, Marshall D. Behrens, Kimberly R. Kalli, Keith L. Knutson. Mayo Clinic, Rochester, MN
3477: Discovery and validation of methylation markers for early detection of endometrial cancer
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Nicolas A. Wentzensen1, Jamie Bakkum2, Keith Killian3, Viji Shridhar2, Lisa Adams3, Richard Guido4, Lori D'Ambrosio4, Patricia Luhn1, Joshua Sampson1, Hannah Yang1, Louise Brinton1, Jolanta Lissowska5, Karl Podratz2, Mark Sherman1. 1NCI-DCEG, Bethesda, MD; 2Mayo Clinic, Rochester, MN; 3NCI-CCR, Bethesda, MD; 4Magee Women's Hospital of the UPMC system, Pittsburgh, PA; 5. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
3478: Gene expression profiles from exfoliated cervical cells identify potential biomarkers predictive of HPV16 clearance or persistence
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Diego Altomare1, Susannah Kassler1, Carolyn Banister1, Amy Messersmith1, Saundra Glover2, Lucia Pirisi-Creek3, Kim E. Creek1. 1SCCP/USC Campus College of Pharmacy, Columbia, SC; 2Arnold School of Public Health - Univ. of South Carolina, Columbia, SC; 3Pathology, Microbiology & Immunology / USC School of Medicine, Columbia, SC
3479: Sensitivity of endometrial cancer cells to inhibitors targeting different nodes of the PI3K pathway and their combination with a MEK inhibitor
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Matthew J. Wongchenko, Yinghui Guan, Marie-Claire Wagle, Lisa Ryner, Shan Lu, Hartmut Koeppen, Garret Hampton, Mark Lackner, Yulei Wang, Yibing Yan. Genentech, Inc., South San Francisco, CA
3480: Impact of a second opinion for sex cord stromal tumors through expression and molecular analysis of FOXL2: a study of the GINECO group and TMRO network.
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Thibaut Goulvent1, Denis Maillet2, Ruth Rimokh1, Philippe Cassier2, Marie-Cecile Vacher-Lavenu3, Pierre Meeus2, Patricia Pautier4, Pierre Duvillard4, Jerome Alexandre3, Eric Pujade-Laurraine5, Mojgan Devouassoux-Shisheboran6, Isabelle Treilleux2, Isabelle Ray-coquard2. 1Cancer Research Center of Lyon (CRCL), Lyon, France; 2Centre Léon Bérard, Lyon, France; 3Hôpital Cochin, Paris, France; 4Institut Gustave Roussy, Paris, France; 5Hôtel Dieu, Paris, France; 6Hôpital de la Croix-Rousse, Lyon, France
3481: Development of personalized paclitaxel therapy (IG-001) for ovarian cancer
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Larn Hwang, Chao Hsiao, Kouros Motamed, Vuong Trieu. IgDraSol, Fountain Valley, CA
3482: Directly Detect High Risk HPV Oncogenes E6/E7 mRNAs from Pap Smear Samples without RNA Purification and RT-PCR
Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
Aiguo Zhang, Lulu Zhang, Rachel Chuang, Xining Zhu, Rachel Diaz, Lily Chen. DiaCarta, Hayward, CA